Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses how vulnerable patients can be identified in the treatment of myeloma. There is an unmet need among patients with myeloma where the maximum benefit of precision treatments is not met and toxicity remains a high threat. Various scoring systems such as the International Myeloma Working Group (IMWG) frailty score aim to identify vulnerable patients, but such scoring systems may fail to differentiate between host response biology and myeloma related morbidities. Prof. Cook also mentions potential alternative biomarkers such as senescent T-cells. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.